Lanreotide acetate (Somatuline Depot Injection, Tercica) has been approved for the treatment of acromegaly, a rare and potentially life-threatening disease in adults. Abnormal secretion of growth hormone (GH) is commonly caused by a benign tumor in the pituitary gland.
Lanreotide acetate (Somatuline Depot Injection, Tercica) has been approved for the treatment of acromegaly, a rare and potentially life-threatening disease in adults. Abnormal secretion of growth hormone (GH) is commonly caused by a benign tumor in the pituitary gland.
Carriers of a rare, genetic condition called Gaucher’s disease, compared with the general public, have a five-times-greater risk of developing Parkinson’s disease (PD). A study from the National Institutes of Health suggests that mutations in the gene responsible for Gaucher’s disease are among the most significant risk factors found to date for PD.